The predominance of IgG4 responses is reminiscent of what was observed in VAX003 participants compared to RV144 participants [7,19,20]

The predominance of IgG4 responses is reminiscent of what was observed in VAX003 participants compared to RV144 participants [7,19,20]. value was >0.3 for the respective monoclonal antibodies. If no specificity offered a value >0.3, the sample was designated while unspecified. The table was sorted by treatment group and time from analysis.(XLSX) ppat.1009101.s003.xlsx (49K) GUID:?9FC5C424-0630-4C8F-B808-202AC433224B S4 Table: Neutralization titers of CRF01_AE viruses following HIV-1 illness. Samples were assessed at 1- and 3- years post-diagnosis. aBreadth = % of viruses neutralized from your panel of 14 subtype AE viruses (top) with an ID40>40. bPotency = Geometric mean titer (ID50) of all viruses. Non-specific neutralization as mediated by MuLV. Plasma that neutralized MuLV ID50 >20 was excluded from analysis (N = 45 samples). The table was sorted by MuLV neutralization, Treatment Group, and Yr from Analysis.(XLSX) ppat.1009101.s004.xlsx (52K) GUID:?2D5314A2-2EC1-4415-9C7A-EAAAA271E0F5 S5 Table: Significant correlations between Fc binding features measured at 6 months and set point viral weight in placebo participants. Spearman correlations were evaluated between 816 Fc binding reactions and set point viral weight. Only correlations with Spearman Rho 0.5 and significant p-values after false finding rate corrections with 0.5 are reported.(XLSX) ppat.1009101.s005.xlsx (9.4K) GUID:?D51D5DA3-4B57-4EDE-9C26-FFB73DA088D7 S1 Fig: Dynamics of IgG subclasses between RV144 vaccine and placebo recipients following infection. The proportion displayed by each subclass is definitely represented at 6 months, 1 and 3 years post-diagnosis. Significant changes in the subclass percentage between time points are shown (*** for p <0.001, ** for p < 0.01 and * for p < 0.5) using Wilcoxon signed-rank test for both vaccine (V) and placebo (P) participants.(TIFF) ppat.1009101.s006.tiff (729K) GUID:?75DEF57B-80EF-4296-A5B1-EFF5EFEC147E S2 Fig: Total IgG and Rabbit polyclonal to ZNF500 IgA binding antibody responses in vaccine (reddish) and placebo (black) recipients. (A) Total IgG and (B) IgA binding to HIV-1 Env antigens at 6 months (N = 24 vaccine, 31 placebo), yr 1 (N = 18 vaccine, 39 placebo) and yr 3 (N = 27 vaccine, 49 placebo) post-HIV-1 analysis. Composite scores are the geometric mean of fold over background per antigen consisting of 9 gp120s, 23 gp140s, 6 V1V2 gp70, and 4 V3 gp70 antigens. p ideals were determined by Mann-Whitney test and adjusted by False Discovery Rate (FDR) for multiple comparisons. Only significant (p<0.05) p Etomoxir (sodium salt) values are demonstrated.(TIFF) ppat.1009101.s007.tiff (540K) GUID:?73F2C611-E17F-4BA7-8470-D9DB4AF564AF S3 Fig: Binding features ranked by the average importance score of each variable at (A) 6 months, (B) year 1 and (C) year 3. Binding features are considered separately for each time point and HIV-1 antigen. Variables having Etomoxir (sodium salt) a score above 70% (dashed collection), related to a 30% imply decrease in accuracy, are considered relevant.(TIFF) ppat.1009101.s008.tiff (1.6M) GUID:?F1DDFE29-6DD9-4E57-B841-E80ADB5AF505 S4 Fig: Fc biophysical features associated with treatment arms at 6 months, 1 and 3 years post-diagnosis identified having a multinomial logistic model. IgG4-gp120 reactions and FcR reactions against V1V2 were robustly selected by LASSO to classify treatment arms. Left panel: coefficient weights for the final logistic regression model. Middle panel: percentage of each feature across CV folds and replicates for the features selected in the final logistic regression model. Right panel, top storyline: visualization of the top two logistic regression coefficients by magnitude; vaccine recipients are displayed in reddish and placebo recipients in black. Right panel, bottom plot: performance of the logistic regression classification from repeated cross-validation using actual versus permutated data having a one-sided P-value and for 200 self-employed repetitions; the effect size measured with Cliffs delta demonstrated in the number.(TIFF) ppat.1009101.s009.tiff (2.1M) GUID:?AC8D3FC5-7AAD-460D-BF0C-1D295B42779C S5 Fig: Neutralization of CFR01_AE pseudoviruses of vaccine and placebo recipients at year 1 and year 3 post-HIV-1 diagnosis. (A) Neutralization breadth (top) and potency (bottom) of vaccine (in reddish) and placebo (in black) recipients using the panel of 14 AE pseudoviruses compared in aggregate using Mann-Whitney t checks. (B) Spearman correlations of neutralization breadth and potency (geometric mean titer (GMT)) of placebo (top) and vaccine (bottom) recipients at yr 1 (N = 12 vaccine, 25 placebo), and 3 (N = 26 vaccine, 43 placebo), post-diagnosis. Neutralization breadth is the percentage of viruses neutralized out of a panel of Etomoxir (sodium salt) 14 CRF01_AE pseudoviruses.(TIFF) ppat.1009101.s010.tiff (877K) GUID:?A6657401-EE57-48AD-BD16-6EB7CA9FD20B S6 Fig: Autologous neutralizing antibody responses in RV144 vaccine and placebo recipients and responses across participants within treatments organizations. (A-B) Longitudinal autologous neutralization in vaccine (N = 9, reddish) Etomoxir (sodium salt) and placebo (N = 14, black) recipients following HIV-1 analysis. (C-D) Neutralization reactions against envelopes with or without residues associated with vaccine effectiveness in.